This study will evaluate the efficacy and safety of sequential administration of Tarceva and gemcitabine/platinum chemotherapy in patients with stage IIIb/IV non-small cell lung cancer. Patients will be randomized to receive Tarceva (150 mg po) or placebo on days 15-28 of a 4 week cycle of intravenous platinum-based chemotherapy, for a total of 6 cycles. The anticipated time on study treatment is until disease progression or unacceptable toxicity.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
154
150 mg orally daily Days 15 to 28 of each 4-week cycle for 6 cycles, followed by 150 mg orally daily
orally daily Days 15 to 28 of each 4-week cycle for 6 cycles, followed by daily oral application
1250 mg/m2 iv Days 1 and 8 of each 4-week cycle, 6 cycles
Unnamed facility
Campbelltown, Australia
Unnamed facility
Camperdown, Australia
Unnamed facility
Liverpool, Australia
Percentage of Participants With Non-Progression at Week 8 as Assessed by Response Evaluation Criteria in Solid Tumors (RECIST)
Non-progression defined as documented best overall tumor response of complete response (CR), partial response (PR), or stable disease (SD; where SD was maintained for greater than \[\>\]8 weeks) per RECIST. Investigator's assessment of response used in all analyses. CR equals (=)disappearance of all target lesions; PR=at least a 30 percent (%) decrease in sum of longest diameter (LD) of target lesions, taking as reference the baseline sum LD; SD=neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for disease progression, taking as reference smallest sum LD since treatment started.
Time frame: Week 8
Percentage of Participants With Non-Progression at Week 16 as Assessed by RECIST
Non-progression defined as documented best overall tumor response of CR, PR, or SD (where SD was maintained for \>16 weeks) per RECIST.
Time frame: Week 16
Percentage of Participants With Confirmed CR or PR as Assessed by RECIST
CR=disappearance of all target lesions; PR=at least a 30% decrease in sum of LD of target lesions, taking as reference the baseline sum LD.
Time frame: Screening/Baseline, Day 22 of Cycles 2, 4 and 6 and every 8 weeks in Post-Study and Off-Study Phases
Duration of Response
Duration of Response was defined similarly for complete responders and partial responders. CR was defined as the date CR was first recorded to the date on which PD was first noted or date of death. PR was defined as the date the first PR was recorded to the date of the first observation of PD or date of death.
Time frame: Screening/Baseline, Day 22 of Cycles 2, 4 and 6 and every 8 weeks in Post-Study and Off-study Phases
Time to Progression
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
75 mg/m2 iv Day 1 of each 4.wek cycle, 6 cycles; or carboplatin
5 x AUC iv Day 1 of each 4.week cycle, 6 cycles; or cisplatin
Unnamed facility
Guangzhou, China
Unnamed facility
Guangzhou, China
Unnamed facility
Shanghai, China
Unnamed facility
Shanghai, China
Unnamed facility
Hong Kong, Hong Kong
Unnamed facility
Jakarta, Indonesia
Unnamed facility
Jakarta, Indonesia
...and 9 more locations
Time to progression was defined as the interval between the day of randomization and the first documentation of PD. Participants who were withdrawn from the study without documented progression and for whom there exists CRF evidence that evaluations have been made, were censored at 1) the date of the last tumor assessment, 2) last date in the drug log, or 3) last date of follow-up when the participant was known to be progression free, whichever was last. Participants without post-baseline tumor assessments but known to be alive were censored at the time of randomization.
Time frame: Screening/Baseline, Day 22 of Cycles 2, 4 and 6 and every 8 weeks in Post-Study and Off-Study Phases
Progression-Free Survival (PFS)
PFS was defined as the interval between the day of randomization and the date of first documentation of progressive disease or date of death, whichever came first.
Time frame: Screening/Baseline, Day 22 of Cycles 2, 4 and 6 and every 8 weeks in Post-Study and Off-Study Phases
Overall Survival
Overall Survival (OS) was defined as the time from the date of randomization to the date of death, regardless of the cause of death. Participants who were alive at the time of the analysis were censored at the date of the last follow-up assessment.
Time frame: Date of randomization until date of death or date of last follow-up assessment